ACRS EBITDA Growth
Aclaris Therapeutics Inc · EBITDA Growth
ACRS EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-30.15%period ending
ACRS TTM EBITDA YoY % (-142.54% → -30.15%)
Year-over-year change
High-resolution chart · PNG
ACRS ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -30.1509% | |
| -32.206% | |
| -32.7307% | |
| -2.4421% | |
| 28.781% | |
| 47.0001% | |
| 55.2414% | |
| 46.0378% | |
| 21.0089% | |
| -6.2551% | |
| -36.9786% | |
| -36.9426% | |
| -22.7708% | |
| -30.8994% | |
| -30.8652% | |
| -44.3963% | |
| -76.1378% | |
| -59.8722% | |
| -37.8963% | |
| -13.706% | |
| 23.9808% | |
| 38.6855% | |
| 45.4424% | |
| 52.214% | |
| 40.8308% | |
| 35.3193% | |
| 28.9312% | |
| 1.9305% | |
| -0.2655% | |
| -28.0709% | |
| -69.1196% | |
| -86.9722% | |
| -111.468% | |
| -85.9375% | |
| -47.5453% | |
| -38.3277% | |
| -19.9913% | |
| -54.1276% | |
| -133.7833% | |
| -126.7616% | |
| -297.4756% | |
| -227.6759% | |
| -142.542% |